Evidence map›Paper›PMID 38683174›Full record

Observational studyBiomolecules & biomedicine2024

Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina.

Nermin Salkić, Mirela Bašić Denjagić, Nađa Zubčević, Renata Tamburić, Azra Husić Selimović, Emil Babić, Milenko Bevanda, Aida Saray, Predrag Jovanović, Zoran Tošić and 2 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Biomolecules & biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nermin SalkićDepartment of Internal Medicine, School of Medicine Tuzla, University of Tuzla, Tuzla, Bosnia and Herzegovina.
Mirela Bašić DenjagićDepartment of Gastroenterology and Hepatology, University Clinical Center of Tuzla, Tuzla, Bosnia and Herzegovina.
Nađa ZubčevićClinic of Gastroenterohepatology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Renata TamburićClinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina.
Azra Husić SelimovićDepartment of Internal Medicine, General Hospital "Abdulah Nakaš" Sarajevo, Sarajevo, Bosnia and Herzegovina.
Emil BabićDepartment of Gastroenterology and Hepatology, University Clinical Hospital of Mostar, Mostar, Bosnia and Herzegovina.
Milenko BevandaDepartment of Gastroenterology and Hepatology, University Clinical Hospital of Mostar, Mostar, Bosnia and Herzegovina.
Aida SarayClinic of Gastroenterohepatology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Predrag JovanovićDepartment of Internal Medicine, School of Medicine Tuzla, University of Tuzla, Tuzla, Bosnia and Herzegovina; Department of Gastroenterology and Hepatology, University Clinical Center of Tuzla, Tuzla, Bosnia and Herzegovina.
Zoran TošićDepartment of Gastroenterology, Health Center Brčko, Brčko, Bosnia and Herzegovina.
Aleksandar DobrovoljskiClinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina.
Tatjana BaraćClinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management.

Indexed as

Antibodies, Monoclonal, HumanizedAdultBosnia and HerzegovinaColitis, UlcerativeCrohn DiseaseFemaleGastrointestinal AgentsHumansInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedGastrointestinal Agentsvedolizumab

Identifiers

PMID38683174
PMCPMC11379020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.